Related Experiment Videos
Novel peptide conjugates for tumor-specific chemotherapy
M Langer1, F Kratz, B Rothen-Rutishauser
1Institute of Biochemistry, University of Leipzig, Talstrasse 33, D-04103 Leipzig, Germany.
Journal of Medicinal Chemistry
|April 20, 2001
Summary
Coupling anticancer drugs to peptides like Neuropeptide Y (NPY) offers a promising strategy for targeted cancer chemotherapy. An acid-sensitive conjugate demonstrated selective tumor cell killing by releasing daunorubicin near the nucleus.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Cancer chemotherapy faces limitations due to severe side effects from unselective drug distribution.
- Targeted drug delivery aims to improve anticancer agent efficacy by selectively targeting tumor cells.
Purpose of the Study:
- To investigate the potential of peptide-drug conjugates for selective cancer chemotherapy.
- To design and evaluate Neuropeptide Y (NPY)-anthracycline conjugates for neuroblastoma treatment.
Main Methods:
- Synthesized three NPY-anthracycline conjugates with varying linker stability (acid-sensitive hydrazone and stable amide bonds).
- Assessed receptor binding affinity using the human neuroblastoma cell line SK-N-MC (NPY Y(1) receptor subtype).
- Evaluated cytotoxic activity via XTT assay and intracellular drug localization using confocal microscopy.
Main Results:
- All conjugates exhibited receptor binding affinities between 25-51 nM.
- Only the conjugate with the acid-sensitive hydrazone bond ([C(15)]-NPY-Dauno-HYD) displayed significant cytotoxic activity comparable to free daunorubicin.
- Cytotoxicity was confirmed as NPY Y(1) receptor-mediated, with the active conjugate releasing daunorubicin near the nucleus.
Conclusions:
- Peptide-drug conjugates, particularly those with acid-sensitive linkers, represent a viable approach for targeted cancer therapy.
- The NPY-daunorubicin conjugate with a hydrazone linker shows promise for selective neuroblastoma treatment by enabling targeted drug release.
- Understanding intracellular drug localization is crucial for optimizing the design of effective peptide-drug conjugates.